Alexander Varond

Alexander Varond brings more than 15 years of FDA legal experience, building on earlier work as a biomedical engineer in the medical device industry. Before founding Varond Law & FDA Strategy, he co-chaired Goodwin's FDA litigation practice and served as a partner in the firm's life sciences group.

Alex advises drug, biotech, and medical device companies on a wide range of FDA regulatory matters, with deep expertise in orphan drug development, accelerated approval pathways, and regulatory flexibility. He also counsels on advertising and promotion and exclusivity issues, and regularly advises on corporate offerings, transactions, and licensing.

Prior to joining Goodwin in 2017, Alex was a senior associate at Hyman, Phelps & McNamara, widely considered one of the premier FDA law firms in the country. Having spent 12 years in Washington, D.C., he maintains extensive ties to FDA, the FDA bar, and the broader regulatory community there.

Alex cares deeply about patients and patient advocacy. He is a former board member of Ogden CARES, an ultrarare disease patient advocacy organization. He regularly trains in-house client teams on drug and biologic development, regulatory strategy, and FDA compliance, and has lectured on FDA regulatory law at graduate engineering, law, and business schools.

Alex holds a J.D. from George Washington University Law School and a B.S. from UC San Diego, where he double-majored in biomedical engineering and management science (economics). During law school, he externed at the U.S. International Trade Commission and clerked at NuVasive (now Globus Medical). He is admitted to the bars of California and the District of Columbia.